United States - English - NLM (National Library of Medicine)

biomedical research foundation of northwest louisiana - ammonia n-13 (unii: 9oqo0e343z) (ammonia n-13 - unii:9oqo0e343z) - ammonia n-13 37.5 mci in 1 ml - ammonia n 13 injection, usp is indicated for diagnostic positron emission tomography (pet) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. none pregnancy category c animal reproduction studies have not been conducted with ammonia n 13 injection.  it is also not known whether ammonia n 13 injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  ammonia n 13 injection should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excreted in human milk.  because many drugs are excreted in human milk and because of the potential for radiation exposure to nursing infants from ammonia n 13 injection, use alternative infant nutrition sources (e.g. stored breast milk or infant formula) for 2 hours (>10 half-lives of radioactive decay for n 13 isotope) after administration of the drug or avoid use of the drug, ta

United States - English - NLM (National Library of Medicine)

biomedical research and development inc - isopropyl alcohol (unii: nd2m416302) (isopropyl alcohol - unii:nd2m416302) - antiseptic - hand sanitizer to help reduce bacteria that potentially can cause disease. - for use when soap and water are not available. - in children less than 2 months of age - on open skin wounds stop use and ask a doctor if irritation or rash occurs. these may be signs of a serious condition.

United States - English - NLM (National Library of Medicine)

biomedical research foundation of northwest louisiana - sodium fluoride f-18 (unii: 9l75099x6r) (fluoride ion f-18 - unii:4m4we5n2ge) - fluoride ion f-18 200 mci in 1 ml - sodium fluoride f 18 injection, usp is indicated for diagnostic positron emission tomography (pet) imaging of bone to define areas of altered osteogenic activity. none. pregnancy category c any radiopharmaceutical including sodium fluoride f 18 injection has a potential to cause fetal harm. the likelihood of fetal harm depends on the stage of fetal development, and the radionuclide dose. animal reproduction studies have not been conducted with sodium fluoride f 18 injection. prior to the administration of sodium fluoride f 18 injection to women of childbearing potential, assess for presence of pregnancy. sodium fluoride f 18 injection should be given to a pregnant woman only if clearly needed. it is not known whether sodium fluoride f 18 injection is excreted into human milk. because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to interrupt nursing after administration of sodium fluoride f

United States - English - NLM (National Library of Medicine)

biomedical research foundation of northwest louisiana - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f-18 300 mci in 1 ml - fludeoxyglucose f 18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation d

United States - English - NLM (National Library of Medicine)

biomedical research foundation of northwest louisiana - fludeoxyglucose f-18 (unii: 0z5b2cjx4d) (fludeoxyglucose f-18 - unii:0z5b2cjx4d) - fludeoxyglucose f 18 injection usp is indicated for positron emission tomography (pet) imaging in the following settings: for assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. none risk summary data from published case series and case reports describe fludeoxyglucose f 18 injection crossing the placenta with uptake by the fetus (see data). all radiopharmaceuticals have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation d

Singapore - English - HSA (Health Sciences Authority)

mp biomedicals asia pacific pte. ltd. - microbiology - the mp diagnostics assure h. pylori rapid test is an immunochromatographic test device intended for the rapid detection of igg antibodies to helicobacter pylori in human serum, plasma or whole blood. it is intended as a clinical diagnostic test for diagnosing infection with h. pylori in patients with gastric disorders. in addition, the presence of antibodies to a recombinant current infection marker (cim) is indicative of current infection.

Singapore - English - HSA (Health Sciences Authority)

mp biomedicals asia pacific pte. ltd. - immunology - the mp diagnostics assure hev igm rapid test is an immunochromatographic test device intended for the rapid detection of igm antibodies to hepatitis e virus (hev) in human serum, plasma or whole blood. it is intended as a clinical diagnostic test for diagnosing infection with hepatitis e.

Singapore - English - HSA (Health Sciences Authority)

mp biomedicals asia pacific pte. ltd. - microbiology - it is an immunochromatographic test device intended for the rapid detection of antibodies to m. tuberculosis in human serum, plasma or whole blood. it is intended as a supplementary and not a conclusive diagnostic test for tuberculosis. the results of this test require molecular tests and/or bacteriology tests (smear test and/or culture) for confirmatory diagnosis of tuberculosis infection.

Singapore - English - HSA (Health Sciences Authority)

mp biomedicals asia pacific pte. ltd. - immunology - the mp diagnostics (mpd) hbsag elisa 4.1 is an enzyme-linked immunosorbent assay (elisa) intended for qualitative detection of hbsag in human serum or plasma samples. it is intended for screening of blood donors and for diagnosing of patients related to infection with hepatitis b virus

Singapore - English - HSA (Health Sciences Authority)

mp biomedicals asia pacific pte. ltd. - immunology - the mp diagnostics hcv blot 3.0 is a qualitative enzyme immunoassay for the in vitro detection of antibodies to hcv in human serum or plasma. it is intended for use as a more specific supplemental test on specimens found repeatedly reactive using specific procedures such as elisa.